Skip to main content
Top
Published in: Diabetologia 10/2010

01-10-2010 | Article

MKR mice have increased dynamic glucose disposal despite metabolic inflexibility, and hepatic and peripheral insulin insensitivity

Authors: B. Vaitheesvaran, D. LeRoith, I. J. Kurland

Published in: Diabetologia | Issue 10/2010

Login to get access

Abstract

Aims/hypothesis

Recent work has shown that there can be significant differences when glucose disposal is assessed for high-fat induced insulin resistance by static clamp methods vs dynamic assessment during a stable isotope i.p. glucose tolerance test. MKR mice, though lean, have severe insulin resistance and decreased muscle fatty acid oxidation. Our goal was to assess dynamic vs static glucose disposal in MKR mice, and to correlate glucose disposal and muscle–adipose–liver flux interactions with metabolic flexibility (indirect calorimetry) and muscle characteristics.

Methods

Stable isotope flux phenotyping was performed using [6,6-2H2]glucose, [U-13C6]glucose and [2-13C]glycerol. Muscle triacylglycerol (TAG) and diacylglycerol (DAG) content was assessed by thin layer chromatography, and histological determination of fibre type and cytochrome c activity performed. Metabolic flexibility was assessed by indirect calorimetry.

Results

Indirect calorimetry showed that MKR mice used more glucose than FVB/N mice during fasting (respiratory exchange ratio [RER] 0.88 vs 0.77, respectively). Compared with FVB/N mice, MKR mice had faster dynamic glucose disposal, despite increased whole-muscle DAG and TAG, and similar hepatic glucose production with higher fasting insulin and unchanged basal glucose. Fed MKR muscle had more glycogen, and increased levels of GLUT1 and GLUT4 than FVB/N muscle. Histology indicated that MKR soleus had mildly decreased cytochrome c activity overall and more type II (glycolytic) fibres compared with that in FVB/N mice.

Conclusions/interpretation

MKR muscle adapts to using glucose, with more type II fibres present in red muscle. Fasting RER is elevated and glucose disposal during an i.p. glucose tolerance test is accelerated despite increased muscle DAG and TAG. Metabolic inflexibility may result from the compensatory use of fuel that can be best utilised for energy requirements; static vs dynamic glucose disposal assessments may measure complementary aspects of metabolic flexibility and insulin sensitivity.
Literature
1.
go back to reference Fernandez AM, Kim JK, Yakar S et al (2001) Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926–1934CrossRefPubMed Fernandez AM, Kim JK, Yakar S et al (2001) Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926–1934CrossRefPubMed
2.
go back to reference Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D (2002) Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest 109:347–355PubMed Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D (2002) Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest 109:347–355PubMed
3.
go back to reference Kim H, Haluzik M, Asghar Z et al (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770–1778CrossRefPubMed Kim H, Haluzik M, Asghar Z et al (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770–1778CrossRefPubMed
4.
go back to reference Xu J, Chang V, Joseph SB et al (2004) Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 145:1087–1095CrossRefPubMed Xu J, Chang V, Joseph SB et al (2004) Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 145:1087–1095CrossRefPubMed
5.
go back to reference Haluzik M, Gavrilova O, LeRoith D (2004) Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic–euglycemic clamp studies. Endocrinology 145:1662–1667CrossRefPubMed Haluzik M, Gavrilova O, LeRoith D (2004) Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic–euglycemic clamp studies. Endocrinology 145:1662–1667CrossRefPubMed
6.
go back to reference Vaitheesvaran B, Chueh FY, Xu J et al (2010) Advantages of dynamic “closed loop” stable isotope flux phenotyping over static “open loop” clamps in detecting silent genetic and dietary phenotypes. Metabolomics 6:180–190CrossRefPubMed Vaitheesvaran B, Chueh FY, Xu J et al (2010) Advantages of dynamic “closed loop” stable isotope flux phenotyping over static “open loop” clamps in detecting silent genetic and dietary phenotypes. Metabolomics 6:180–190CrossRefPubMed
7.
go back to reference Xu J, Xiao G, Trujillo C et al (2002) Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 277:50237–50244CrossRefPubMed Xu J, Xiao G, Trujillo C et al (2002) Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 277:50237–50244CrossRefPubMed
8.
go back to reference Xu J, Lee WN, Xiao G et al (2003) Determination of a glucose-dependent futile recycling rate constant from an intraperitoneal glucose tolerance test. Anal Biochem 315:238–246CrossRefPubMed Xu J, Lee WN, Xiao G et al (2003) Determination of a glucose-dependent futile recycling rate constant from an intraperitoneal glucose tolerance test. Anal Biochem 315:238–246CrossRefPubMed
9.
go back to reference Xu J, Gowen L, Raphalides C et al (2006) Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse. Diabetes 55:3372–3380CrossRefPubMed Xu J, Gowen L, Raphalides C et al (2006) Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse. Diabetes 55:3372–3380CrossRefPubMed
10.
go back to reference Xu J, Lee WN, Phan J, Saad MF, Reue K, Kurland IJ (2006) Lipin deficiency impairs diurnal metabolic fuel switching. Diabetes 55:3429–3438CrossRefPubMed Xu J, Lee WN, Phan J, Saad MF, Reue K, Kurland IJ (2006) Lipin deficiency impairs diurnal metabolic fuel switching. Diabetes 55:3429–3438CrossRefPubMed
11.
go back to reference Kupke IR, Zeugner S (1978) Quantitative high-performance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5-microliter samples to the silica-gel layer. J Chromatogr 146:261–271CrossRefPubMed Kupke IR, Zeugner S (1978) Quantitative high-performance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5-microliter samples to the silica-gel layer. J Chromatogr 146:261–271CrossRefPubMed
12.
go back to reference Round JM, Matthews Y, Jones DA (1980) A quick, simple and reliable histochemical method for ATPase in human muscle preparations. Histochem J 12:707–710CrossRefPubMed Round JM, Matthews Y, Jones DA (1980) A quick, simple and reliable histochemical method for ATPase in human muscle preparations. Histochem J 12:707–710CrossRefPubMed
13.
go back to reference Heron-Milhavet L, Haluzik M, Yakar S et al (2004) Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology 145:4667–4676CrossRefPubMed Heron-Milhavet L, Haluzik M, Yakar S et al (2004) Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology 145:4667–4676CrossRefPubMed
14.
go back to reference Zhao H, Yakar S, Gavrilova O et al (2004) Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53:2901–2909CrossRefPubMed Zhao H, Yakar S, Gavrilova O et al (2004) Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53:2901–2909CrossRefPubMed
15.
go back to reference Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619–2630CrossRefPubMed Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619–2630CrossRefPubMed
16.
go back to reference Kim H, Haluzik M, Gavrilova O et al (2004) Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47:2215–2225CrossRefPubMed Kim H, Haluzik M, Gavrilova O et al (2004) Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47:2215–2225CrossRefPubMed
17.
go back to reference Toyoshima Y, Gavrilova O, Yakar S et al (2005) Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology 146:4024–4035CrossRefPubMed Toyoshima Y, Gavrilova O, Yakar S et al (2005) Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology 146:4024–4035CrossRefPubMed
18.
go back to reference Kawashima Y, Chen J, Sun H et al (2009) Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia 52:1434–1441CrossRefPubMed Kawashima Y, Chen J, Sun H et al (2009) Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Diabetologia 52:1434–1441CrossRefPubMed
19.
go back to reference Kim CH, Pennisi P, Zhao H et al (2006) MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab 291:E298–E305CrossRefPubMed Kim CH, Pennisi P, Zhao H et al (2006) MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab 291:E298–E305CrossRefPubMed
20.
go back to reference Asghar Z, Yau D, Chan F, Leroith D, Chan CB, Wheeler MB (2006) Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia 49:90–99CrossRefPubMed Asghar Z, Yau D, Chan F, Leroith D, Chan CB, Wheeler MB (2006) Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia 49:90–99CrossRefPubMed
Metadata
Title
MKR mice have increased dynamic glucose disposal despite metabolic inflexibility, and hepatic and peripheral insulin insensitivity
Authors
B. Vaitheesvaran
D. LeRoith
I. J. Kurland
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1827-4

Other articles of this Issue 10/2010

Diabetologia 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.